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Abstract
Background: Delirium is a common and serious clinical syndrome which is often missed in routine clinical care.
The core cognitive feature is inattention. We developed a novel bedside neuropsychological test for assessing
inattention in delirium implemented on a smartphone platform (DelApp). We aim to evaluate the diagnostic
performance of the DelApp in a representative cohort of older hospitalised patients.
Methods: This is a prospective study of older non-scheduled hospitalised patients (target n = 500, age ≥ 65),
recruited from elderly care and acute orthopaedic wards. Exclusion criteria are: non-English speakers; severe vision
or hearing impairment; photosensitive epilepsy.
A structured reference standard delirium assessment based on DSM-5 criteria will be used, which includes a
cognitive test battery administered by a trained assessor (Orientation-Memory-Concentration Test, Abbreviated
Mental Test-10, Delirium Rating Severity Scale-Revised-98, digit span, months and days backwards, Vigilance A’ test)
and assessment of arousal (Observational Scale of Level of Arousal, Richmond Agitation Sedation Scale). Prior
change in cognition will be documented using the Informant Questionnaire on Cognitive Decline in the Elderly.
Patients will be categorized as delirium (with/without dementia), possible delirium, dementia, no cognitive
impairment, or undetermined.
A separate assessor (blinded to diagnosis and assessments) will administer the DelApp index test within 3 h of the
reference standard assessment. The DelApp comprises assessment of arousal (score 0-4) and sustained attention
(score 0-6), yielding a total score between 0 and 10 (higher score = better performance). Outcomes (length of stay,
mortality and discharge location) will be collected at 12 weeks.
We will evaluate a priori cutpoints derived from a previous case-control study. Measures of the accuracy of DelApp
will include sensitivity, specificity, positive and negative predictive values, and area under the ROC curve. We plan
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repeat assessments on up to 4 occasions in a purposive subsample of 30 patients (15 delirium, 15 no delirium) to
examine changes over time.
Discussion: This study evaluates the diagnostic test accuracy of a novel smartphone test for delirium in a representative
cohort of older hospitalised patients, including those with dementia. DelApp has the potential to be a convenient,
objective method of improving delirium assessment for older people in acute care.
Trial registration: Clinical trials.gov, NCT02590796. Registered on 29 Oct 2015. Protocol version 5, dated 25 July 2016.
Keywords: Delirium, Dementia, Attention, Neuropsychological test, Cognition, Consecutive series, Smartphone test,
Diagnostic accuracy study, Prospective study
Background
Delirium in hospitalised older patients
Delirium is a common and severe neuropsychiatric syn-
drome characterized by acute and fluctuating impairments
in arousal, attention and cognition. It affects at least 1 in 8
general hospital patients [1–3] and is commonly triggered
by acute illness, trauma or medications. It is independently
associated with poor outcomes including higher morbidity,
mortality, longer hospital stay, and an increased risk of new
or accelerated cognitive impairment [4–6]. Moreover, delir-
ium is often distressing for patients and their carers [7].
The economic impact of delirium is also large [8].
Despite this, delirium remains poorly detected in hospital
with at least two-thirds of cases missed [1]. This failure to
detect delirium remains a major barrier to improving care,
because accurate diagnosis is crucial to ensure prompt treat-
ment of causes, management of risk (e.g. falls, dehydration)
and relief of distress [9]. Therefore, as stated in major
national guidelines and policy documents, improving the
detection of delirium is a priority for the NHS and other
healthcare systems [10, 11].
Neuropsychology of inattention in delirium
The core diagnostic feature of delirium is inattention
[12]. There is significant overlap between the phenom-
enology of delirium and other major differential diagno-
ses including dementia, but inattention is important
diagnostically because it is usually much less prominent
in dementia [13–15]. Differentiating between delirium
and dementia is key to optimal treatment and manage-
ment of the symptoms and underlying causes of these
syndromes.
Although the extent to which different aspects of at-
tention are affected in delirium is poorly understood,
there is some evidence to suggest that the ability to
maintain attention to stimuli over time (i.e. sustained at-
tention) is consistently impaired [13]. This could help
explain the range of performance deficits seen in delir-
ium across a variety of neuropsychological tests, since
staying alert and sustaining attention to the stimulus
material is a requirement of most tests.
Inattention in delirium is currently detected using either
subjective interview-based assessments, a range of cognitive
tests (e.g. digit span, months of the year backwards), or a
combination of both. Subjective assessments and judge-
ments of attention often have inadequate reliability and
require specialist or trained assessors [16]. Most existing
tests of attention have not been formally validated for delir-
ium detection in representative samples of patients with a
broad spectrum of cognitive and behavioural impairments
[17] and are usually not specific to delirium (i.e. they dis-
criminate poorly between delirium and other mental
disorders including dementia [18]). This is likely in part
because many so-called ‘attention’ tests measure a range
of other cognitive functions including memory and execu-
tive function which are known to be also impaired in de-
mentia [19].
In summary, currently available assessments of inatten-
tion have several drawbacks including inadequate discrim-
ination between delirium and dementia and subjectivity.
The lack of well-validated objective tools for attention
assessment in delirium leads to uncertainty over diagnosis,
and is likely a major contributing factor in the low
detection rates of delirium.
Rationale for the study
To help address the need for objective bedside tests of
attention suitable for use in older hospitalised patients
with delirium and/or dementia, we previously developed
a neuropsychological test of sustained and focused atten-
tion implemented on a purpose-built computerised
device called the Edinburgh Delirium Test Box (EDTB;
[13, 20, 21]). We subsequently developed a prototype
software application for smartphones (‘DelApp’) which is
based on the EDTB tasks [22]. Some severely impaired
patients cannot engage with verbal cognitive testing, and
to take account of this the DelApp incorporates an
initial brief assessment of level of arousal, involving
observations and participant’s responses to a sequence
of simple commands.
A pilot single-rater case-control study using the
DelApp showed significantly lower scores in patients
Rutter et al. BMC Geriatrics  (2018) 18:217 Page 2 of 10
with delirium compared to groups with dementia or no
cognitive impairment. Receiver Operating Characteristic
(ROC) curve analyses found excellent accuracy of the
DelApp for discriminating between delirium and demen-
tia and between delirium and cognitively normal con-
trols [22]. These pilot study findings are promising,
suggesting that the DelApp test merits further assess-
ment as a method for objective assessment of attention
in delirium.
Study aims and objectives
The primary objective is to evaluate the diagnostic accuracy
of the DelApp in a representative sample of patients versus
the reference standard. A priori cut points for discriminating
delirium from the whole sample and from dementia, derived
from preceding case-control studies [23], will be evaluated.
The secondary objectives are:
A. To evaluate the DelApp total score as a measure of
delirium severity (construct validity);
B. To determine the association between DelApp total
scores and other measures of attention (i.e. months
of the year backward, days of the week backward,
Vigilance A’ test and counting down from 20 to 1)
(construct validity);
C. To assess if DelApp scores predict important
clinical outcomes: length of stay, mortality at
12 weeks and discharge destination;
D. To determine if DelApp scores are responsive to
changes in delirium status and severity for a person
over time.
E. To assess inter-rater agreement of the DelApp
assessment.
Methods
Study overview
This is a diagnostic accuracy study involving a represen-
tative sample of patients recruited from general and
acute medical hospital wards. We aim to recruit 500 pa-
tients aged 65 years and over from the Royal Infirmary
of Edinburgh and the Glasgow Royal Infirmary,
Scotland, UK. We expect that at least 100 patients will
have delirium [3], and a similar or greater number will
have dementia without delirium [24]. All patients will
be screened in order of arrangement of beds on the
respective wards with no limit on duration of patient
stay, subject to researcher availability. Informed con-
sent will be sought from patients or their relatives or
welfare guardian. The study overview flowchart is
shown in Fig. 1.
The DelApp (index test) will be evaluated against the
reference standard diagnosis of delirium. The index test
and reference standard assessment will be administered
to the same patients by two independent, trained
assessors. The second assessor who administers the
index test will be blinded to the reference standard as-
sessment, the patients’ diagnosis and other clinical infor-
mation to ensure unbiased scoring of the DelApp. Total
test time will be around 15-25 min, with a target interval
of 15-60 min between index and reference standard as-
sessments and a maximum possible interval of 3 h.
A purposive subsample of 30 patients (i.e. 15 with de-
lirium at any of the assessments, and 15 without delir-
ium) will be assessed on up to three further occasions at
least 1 day apart, along with the reference standard, to
evaluate changes in DelApp scores and the reference
standard assessment over time. Inter-rater assessments
of reference standard and index test are planned in 40
patients (20 per recruitment site).
The recruitment period lasted from August 2016 to
March 2018. Data cleaning and data checks are ongoing
as of April 2018.
Participants
Inclusion criteria
Participants will be included if they are aged 65 years or
over and if they have capacity to provide written, in-
formed consent or if a suitable relative or welfare guard-
ian/attorney is available to provide informed consent on
their behalf.
Exclusion criteria
Participants will be excluded if they have vision or hear-
ing impairment severe enough to preclude testing or
interview or a history of photosensitive epilepsy, or if
they are unable to understand English.
Informed consent and enrolment
Potentially eligible patients will be identified through
discussion of the inclusion and exclusion criteria with a
medical staff member responsible for the care of the pa-
tient. The researcher will also gather information from
the medical staff member about the patient (using a for-
mal checklist) to check for potential issues including if
the patient has deteriorated since first being identified as
eligible, whether the patient is participating in other re-
search and any concerns the family or carers have. If
they are extremely concerned about the patient’s health
or the care that the patient receives, the patient will not
be approached.
Eligible patients will first be approached by a member
of the patient’s clinical care team, who will inform them
that a researcher would like to talk to them about taking
part in a study. If the patient expresses an interest in
taking part then the clinical team member will introduce
the researcher to the patient. Informed consent will be
sought by the researcher, who is trained in conducting
capacity assessment and obtaining consent. Patients will
Rutter et al. BMC Geriatrics  (2018) 18:217 Page 3 of 10
be given an information sheet and have the opportunity
to read it and ask questions. If the researcher judges that
the patient lacks capacity to provide informed consent,
proxy consent will be sought from the nearest relative or
welfare guardian/attorney at the first opportunity in per-
son, or by telephone.
Index test: DelApp
The DelApp (index test) comprises a brief arousal as-
sessment followed by a sustained attention task whereby
participants are instructed to count a number of stars
presented serially on a smartphone screen.
The arousal assessment consists of the following items:
(1) judge whether the patient is awake and responsive,
or if the patient opens their eyes to speech or a touch on
the shoulder for more than 10 s (2 points) or less than
10 s (1 point); (2) ask the patient to say their name or
obey a one-stage command (e.g. lifting one arm) (1
point); and (3) ask the patient to follow an object with
their eyes for 5 s (1 point). This yields a maximum pos-
sible score of 4 indicating that the patient is awake and
able to follow basic commands. Participants who achieve
a score of ≥3 on the arousal assessment proceed with
the attention task. In case of an arousal score below 3,
the assessment ends and the participant receives a total
DelApp score based on the arousal assessment alone.
Assessor instructions for this assessment and a sche-
matic display of items and scoring procedures are pre-
sented in Additional file 1: Table S1 and Figure S1,
respectively.
The attention task requires counting a series of large
white five-pointed stars (approximately 5 cm diameter)
appearing on the screen presented against a black back-
ground (Fig. 2). As the task progresses, distracting tri-
angular shapes appear around the stimuli and the time
delay between stars increases, placing a greater demand
on the participant’s attention. The counting task consists
of 7 trials, the first being a practice trial which is not
scored. Stars and distracting shapes are presented for a
fixed duration of 1000 msec each. The number of stars
and time delays between the stars vary based on a
pre-defined design. The number of stars presented on a
Fig. 1 DelApp study design overview flowchart
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given trial ranges between 2 and 5 stars for trials 1-3, be-
tween 4 and 6 stars for trials 4 and 5, and between 6 and
8 stars for trials 6 and 7. The time delays between stars
vary within the range of 1500-3000 msec for trials 1-5
and 3000-4500 msec for trials 6 and 7. Distracting
shapes are presented in trials 4-7 only, with approxi-
mately twice as many distracting shapes presented in tri-
als 6-7 compared to trials 4-5.
Prior to the start of the counting task, participants
perform a brief visual pre-test whereby they are asked to
identify a single star presented on the smartphone
screen, to check for visual impairment severe enough to
affect performance on the counting task. Testing will
proceed only if the patient correctly identifies the shape.
Assessor instructions and scoring procedures for the
DelApp visual pre-test and attention assessment are pre-
sented in Additional file 1: Table S1.
The DelApp assessment is usually completed
within 5 min, but the time varies between partici-
pants. Trials are scored as correct or incorrect. A
missing answer is considered an incorrect response.
If the participant gives an incorrect answer (or no
answer) twice in a row, the assessment ends. Total
DelApp score consists of the arousal score (score
0-4) and attention score (score 0-6), yielding a total
score between 0 and 10 whereby a score of 10 indi-
cates normal attention.
Reference standard assessment
The reference standard assessment consists of cogni-
tive and delirium assessment tools and observational
scales, supplemented by inspection of the case notes,
discussion with the clinical team and an informant
history if available.
To assess overall cognitive function (including mem-
ory and attention), the Short Orientation-Memory-
Concentration Test (OMCT; [25]) and abbreviated
mental test (AMT10 [26]) will be administered. Atten-
tional function will be measured with a brief attentional
test battery consisting of digit span (forward and back-
ward), months of the year backward (as part of the
OMCT), days of the week backward and the Vigilance ‘A’
test from the Montreal Cognitive Assessment [27]. Sub-
jective feelings of pain at the time of assessment will be
assessed with a 10-point pain thermometer [28].
The Delirium Rating Scale-Revised-98 (DRS-R98 [29])
will be used to assess delirium severity, which requires
inspection of case notes, discussions with staff and add-
itional cognitive testing of short- and long-term memory
and visuospatial function (which are not adequately
captured in the OMCT or AMT10). For details about
assessor instructions and scoring procedures of the
neuropsychological tests used in the reference standard
assessment, see Additional file 2.
Level of arousal is assessed with the Observational
Scale of Level of Arousal (OSLA [20]) and the Richmond
Agitation-Sedation Scale in which the expression “se-
dated” is replaced by “drowsy” [30]. These observational
scales require no extra time with the patient and are
scored directly after the cognitive assessments. Any for-
mal prior diagnosis of dementia will be recorded and, if
available, a relative or other individual who has known
the patient for 10 years will be asked to fill out the
Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE; [31]) to help determine whether
patients had longstanding cognitive decline prior to their
hospital admission. Ascertainment of DSM-5 delirium
will be based on a standardised process using operatio-
nalised DSM-5 criteria which take into account all avail-
able information (i.e. cognitive test scores, observations,
case notes etc.; Table 1).
In view of the transient and fluctuating nature of delir-
ium, we expect that for some patients it will be challen-
ging to determine whether or not they meet all DSM-5
criteria for delirium. These challenging cases will be dis-
cussed in regular group discussions with a delirium ex-
pert (AMJM or DJS) who will be blinded to the index
test scores (DelApp).
Grouping of participants
Patients will be categorised into the following groups:
delirium (with or without dementia), possible delirium,
dementia without delirium, no cognitive impairment,
and undetermined.
Patients will be included in the delirium group if (1)
there is evidence of inattention and other cognitive
Fig. 2 Examples of stimuli used in the DelApp attention test: five-
pointed star without distracting shapes (left; trials 1-3) and with
surrounding distracter shapes (right; trials 4-7)
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problems from the reference standard which cannot be
better attributed to pre-existing cognitive impairment,
and/or (2) if there is positive evidence of delirium in the
24 h prior to the reference standard assessment in the
case notes or as indicated by a senior member of the
clinical team. If patients display some symptoms of delir-
ium, but there is uncertainty about diagnosis due to
missing information (e.g. it is unclear if the problems
represent an acute change from baseline cognitive status,
because no informant is available) then these patients
will be grouped as having possible delirium.
Patients who have a formal diagnosis of dementia and/
or an IQCODE score > 3.82 [32], with no evidence of de-
lirium (specifically no acute change from baseline cogni-
tive status) will be grouped as having dementia.
Patients who show no inattention or other cognitive
problems as indicated by an OMCT score > 20 and an
AMT10 score > 7 and have no acute change from
baseline are grouped as having no cognitive impair-
ment. There must also be no formal diagnosis or
clinical input of dementia (e.g. when the clinical team
suspect that the patient has dementia and he/she is
referred to a memory assessment service).
Patients will be grouped as ‘undetermined’ if all in-
formation is available showing that they present some
degree of delirium symptoms without meeting full
DSM-5 diagnostic criteria for delirium. Thus, this is
likely subsyndromal or resolving delirium. Patients
who are currently undergoing clinical investigation for
dementia but where no outcome has been decided
will also be classified as undetermined.
Data management and storage
Data from the reference standard and index assessment, as
well as medical information and IQCODE will be recorded
on paper Case Report Forms. The data on the Case Report
Forms will be transcribed by the researchers into a secure
database created by the Edinburgh Clinical Trials Unit.
Sample size calculation
Of the 500 patients recruited, 20% would be expected to
have delirium [3]. Sample sizes were obtained using a
normal approximation to the binomial distribution to
estimate a 95% confidence interval (CI) for measures of
diagnostic accuracy for delirium. The anticipated confi-
dence interval widths are shown in Table 2 for a range
of levels of diagnostic test performance.
In a sample of 500 patients, as per the original study
protocol, specificity for the delirium versus no delirium
comparison and the delirium versus dementia comparison
can be estimated precisely in all scenarios; sensitivity can be
measured precisely when the diagnostic performance is
good, and moderately precisely in other scenarios (Table 2).
Statistical analysis plan
The statistical analysis plan was prepared by the study
statisticians (CJW, VA).
Primary objective
The diagnostic accuracy of the DelApp versus the reference
standard will be determined using sensitivity, specificity,
and positive and negative predictive values. The DelApp
total score will be analysed in a univariate logistic regres-
sion and ROC curve analysis. From this we will obtain a
measure of the discriminating ability of the DelApp score,
by calculating the Area Under the ROC Curve (AUC). We
will also calculate the optimal cut-off using Youden’s index
[23] to assess if the a priori DelApp cut-off scores are ap-
propriate. These a priori DelApp cut points are 8 for dis-
criminating delirium from the whole sample, and 6 for
discriminating between delirium and dementia [2].
Secondary objectives
Using Spearman correlations, we will evaluate the asso-
ciation between DelApp scores with delirium severity as
measured with the DRS-R98 (secondary objective A)
and tests of attention (digit span, months of the year
backward, days of the week backward, and Vigilance A’;
secondary objective B) to investigate construct validity.
To assess criterion validity, the association between
DelApp total scores and length of stay, mortality at 12 weeks
after study participation and discharge location will be eval-
uated with normal linear models (secondary objective C).
To explore the performance of the DelApp in track-
ing change in attentional functioning and delirium
status, changes in test scores over time (from patients
who have undergone repeat assessments), rescaled to
a common range of values to facilitate comparison
between tests, will be presented in descriptive statis-
tics and graphically, comparing baseline with each of
the other time points (secondary objective D).
Table 2 Precision of sensitivity and specificity estimation
(delirium versus control comparison)
Sample size Parameter True level
of parameter
95% CI
width
500 Sensitivity 0.5 ±0.098
Sensitivity 0.7 ±0090
Sensitivity 0.9 ±0.059
Specificity 0.5 ±0.049
Specificity 0.7 ±0.045
Specificity 0.9 ±0.029
The sensitivity precision in the delirium versus dementia comparison will be
identical to the details outlined above, as the size of the delirium target group
is unchanged. The dementia group is similar in size to the delirium group,
hence the precision of specificity estimation in this comparison will be similar
to that given for sensitivity. These estimates are based on a delirium
prevalence of 20%
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Inter-rater reliability will be evaluated using the Kappa
statistic and its 95% CI (secondary objective E).
Participants with missing data on the primary outcome
measures will be removed from the statistical analysis.
In case of a high proportion of missing data we will con-
sider an imputation approach.
All statistical tests will be two-sided and will be per-
formed using a 0.05 significance level and 95% (two--
sided) CIs will be presented. There will be no statistical
adjustment for multiplicity of analyses; there is a single
primary analysis and the interpretation of secondary
analyses will be suitably cautious to reflect the large
number of variables considered.
For all statistical analyses, the primary analyses will be
unadjusted. We will also present secondary analyses ad-
justed for age, sex, centre and IQCODE.
Monitoring and safety
This study is being monitored by the Academic and
Clinical Central Office for Research and Development
(ACCORD). The assessors will record any adverse
events, serious adverse events, adverse device effects and
serious adverse device effects that might occur during
the assessments in line with the ACCORD guidelines.
When serious, these events will also be reported to the
Medicines and Healthcare products Regulatory Agency.
Training
Researchers at the University of Edinburgh and University
of Glasgow were extensively trained by the Principal In-
vestigator, Co-Investigators and a post-doctoral Research
Fellow (ZT) working on the project. All researchers were
certified in Good Clinical Practice and received compre-
hensive training, using training videos on delirium, obser-
vation of clinicians on hospital wards, role-playing
scenarios and introductory visits to each ward. Further-
more, appropriate training on the use of electronic soft-
ware which maintains medical records was given where
appropriate. The researchers will be observed by experi-
enced clinicians and/or the Research Fellow at regular in-
tervals to ensure quality of assessments.
Dissemination
After data analysis the results of this study will be pub-
lished in appropriate medical academic journals. More-
over, we aim to disseminate this study and its results at
academic delirium related conferences including confer-
ences organised by the European Delirium Association
and American Delirium Society. Patients who explicitly
express a wish to be informed about the research out-
come will be contacted and offered to receive an article
or poster with a lay summary of the study. All academic
papers and posters will be written by the core members
of the research team.
Discussion
There is a need for objective assessment tools for delirium
which are practical and feasible for use in elderly acute
care settings. We developed a novel neuropsychological
test for assessing arousal and sustained attention in delir-
ium, implemented on a smartphone platform (DelApp).
Computer-based tests have potential advantages over
paper and pencil alternatives in clinical practice and at the
bedside. These include standardised instructions, con-
trolled presentation of stimuli and objective scoring
methods. Smartphone-based applications are increasingly
being used in healthcare and computer-based cognitive
testing is now feasible in routine clinical practice [33].
The DelApp provides an easy-to-administer smart-
phone test which has potential to assist assessment of
delirium at the bedside. It is important to evaluate new
methods for delirium assessment such as DelApp in
studies that: (i) employ rigorous diagnostic test accuracy
methods with explicit operationalised diagnostic criteria
(i.e. reference standard); (ii) describe a clear and trans-
parent rationale for group allocation, including those in
whom there is diagnostic uncertainty; and (iii) evaluate
tools in real-world settings, including in patients with
potential difficulties in communication and overlapping
symptom profiles such as dementia. The present study
protocol was designed to meet these criteria.
This study will give new data on performance of
DelApp in detection of delirium in a representative co-
hort of older hospital patients. Further, the research
value of DelApp for detecting inattention but also for
grading severity and tracking change in attentional func-
tion and delirium over time will be evaluated.
Additional files
Additional file 1: This document presents instructions and scoring
procedures for the DelApp arousal and attention assessments. Table S1.
DelApp assessment and scoring procedure (i.e. arousal and attention
assessment). Figure S1. Schematic display of DelApp arousal assessment
and scoring. (PDF 124 kb)
Additional file 2: This document presents a table (Table S2) that
provides additional detail on the instructions and scoring methods of
the neuropsychological tests used in the reference standard
assessment. (PDF 129 kb)
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